 General Electric Co.'s health-care unit agreed to buy several life-science businesses from Thermo Fisher Scientific Inc. for about $1.06 billion, its third biopharmaceutical acquisition in as many years.. The deal with GE, expected to close early this year, includes Thermo Fisher's cell-culture business, which includes media and serums used to manufacture medicines and vaccines. The businesses were put up for sale by Thermo Fisher late last year to expedite European approval of its pending $13.6 billion acquisition of Life...
  